pmid	doi	year	title	Hugo_Symbol
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	MYC
33779481	10.1080/01676830.2021.1904426	2022	Double-hit and triple-hit high-grade B-cell lymphoma of the ocular adnexa.	MYC
34162179	10.3324/haematol.2021.278743	2022	Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.	MYC
34289655	10.3324/haematol.2021.278638	2022	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.	MYC
34304248	10.1038/s41375-021-01347-6	2022	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.	MYC
34392269	10.1097/PAS.0000000000001750	2022	Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.	MYC
34456240	10.1097/PAI.0000000000000967	2022	Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.	MYC
34472720	10.1002/cnr2.1545	2022	Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.	MYC
34510996	10.1080/10428194.2021.1975189	2022	<i>BCL2</i> translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival.	MYC
34519021	10.1111/bjh.17815	2022	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.	MYC
34608246	10.1038/s41379-021-00909-4	2022	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.	MYC
34617271	10.1111/bjh.17874	2022	Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.	MYC
34632715	10.1002/1878-0261.13115	2022	Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma.	MYC
34637146	10.1111/his.14585	2022	EBV<sup>+</sup> high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study.	MYC
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	MYC
34714908	10.1182/bloodadvances.2021005486	2022	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	MYC
34727403	10.1111/pin.13182	2022	AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	MYC
34727830	10.1080/10428194.2021.1998480	2022	Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma.	MYC
34739417	10.1097/PAS.0000000000001830	2022	Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma.	MYC
34764434	10.1038/s41379-021-00962-z	2022	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.	MYC
34788985	10.3324/haematol.2021.279631	2022	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing.	MYC
34842019	10.1080/10428194.2021.2008383	2022	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?	MYC
34882582	10.1172/JCI153283	2022	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.	MYC
34910327	10.1111/jop.13269	2022	Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases.	MYC
34951009	10.1111/bjh.17971	2022	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.	MYC
34980601	10.1158/1078-0432.CCR-21-2949	2022	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.	MYC
35013138	10.1038/s41420-021-00622-w	2022	Knockdown of NRMT enhances sensitivity of retinoblastoma cells to cisplatin through upregulation of the CENPA/Myc/Bcl2 axis.	MYC
35031886	10.1186/s43556-021-00066-9	2022	Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.	MYC
35036912	10.1177/2632010X211070774	2022	Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow.	MYC
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	MYC
35046056	10.1158/1078-0432.CCR-21-3617	2022	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.	MYC
35054466	10.3390/life12010073	2022	The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.	MYC
35082399	10.1038/s41417-021-00415-4	2022	CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.	MYC
35091546	10.1038/s41420-022-00833-9	2022	Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.	MYC
35152630	10.3760/cma.j.cn112151-20210826-00604	2022	[Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].	MYC
35183824	10.1016/j.prp.2022.153804	2022	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.	MYC
35198451	10.3389/fonc.2022.834288	2022	Prognostic Value of Radiomic Features of <sup>18</sup>F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells.	MYC
35223507	10.3389/fonc.2022.824632	2022	<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.	MYC
35231992	10.3760/cma.j.issn.0253-2727.2022.01.009	2022	[MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].	MYC
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	MYC
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	MYC
35279534	10.1016/j.theriogenology.2022.02.028	2022	Ascorbic acid regulates mouse spermatogonial stem cell proliferation in a Wnt/β-catenin/ROS signaling dependent manner.	MYC
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	MYC
35297566	10.1111/pin.13223	2022	Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.	MYC
35299080	10.1016/j.anndiagpath.2022.151913	2022	HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies.	MYC
35303910	10.1186/s13045-022-01249-9	2022	Altered pathways and targeted therapy in double hit lymphoma.	MYC
35306137	10.1016/j.cellsig.2022.110311	2022	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.	MYC
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	MYC
35414839	NA	2022	Primary ovarian Burkitt lymphoma: report of a case and review of literature.	MYC
35444774	10.4084/MJHID.2022.018	2022	TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.	MYC
35481444	10.1080/10428194.2022.2064988	2022	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.	MYC
35482553	10.1002/hon.3010	2022	Targeting MYC and BCL2 by a natural compound for double-hit lymphoma.	MYC
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	MYC
35489963	10.1016/j.blre.2022.100967	2022	ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.	MYC
35498426	10.3389/fendo.2022.846357	2022	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.	MYC
35510016	10.7759/cureus.23681	2022	Incidental Pathogenic Fibrin-Associated Diffuse Large B-cell Lymphoma Found During Aorto-Biiliac Bypass.	MYC
35511691	10.1093/ajcp/aqac047	2022	A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.	MYC
35538643	10.1002/cam4.4742	2022	Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.	MYC
35539018	10.1016/j.lrr.2022.100318	2022	A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement.	MYC
35578798	10.1002/jcp.30777	2022	Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells.	MYC
35583405	10.1097/DAD.0000000000002053	2022	Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma.	MYC
35595618	10.1016/j.clml.2022.04.010	2022	Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.	MYC
35652622	10.4149/neo_2022_220318N300	2022	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.	MYC
35657404	10.1007/s00428-022-03342-3	2022	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.	MYC
35696785	10.1016/j.biomaterials.2022.121607	2022	Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma.	MYC
35705274	10.2169/internalmedicine.9711-22	2022	Biclonal diffuse large B-cell lymphoma commonly characterized by partial trisomy 18q involving MALT1 and BCL2.	MYC
35715938	10.1002/cjp2.283	2022	Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.	MYC
35726023	10.1038/s41684-022-00998-x	2022	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	MYC
35774514	10.3389/fgene.2022.827840	2022	A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.	MYC
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	MYC
35787399	10.1016/j.jid.2022.06.005	2022	The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.	MYC
35815807	10.1158/0008-5472.CAN-21-2454	2022	The X-Linked Helicase DDX3X Is Required for Lymphoid Differentiation and MYC-Driven Lymphomagenesis.	MYC
35846201	10.1002/jha2.310	2022	Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report.	MYC
35869021	10.1016/j.clml.2022.06.011	2022	Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.	MYC
35882439	10.1182/bloodadvances.2022007541	2022	Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.	MYC
35884496	10.3390/cancers14143434	2022	Classifying Germinal Center Derived Lymphomas-Navigate a Complex Transcriptional Landscape.	MYC
35885931	10.3390/genes13071144	2022	Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group.	MYC
35916333	10.1002/dc.25027	2022	HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.	MYC
35916644	10.1097/QAI.0000000000003069	2022	Diffuse Large B-cell Lymphoma in the public-sector of Johannesburg, South Africa, in the era of widescale Anti-retroviral therapy use.	MYC
35920412	10.1002/jbt.23185	2022	Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro.	MYC
35932211	10.1002/hon.3061	2022	Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.	MYC
35952327	10.1200/JCO.22.00597	2022	Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.	MYC
35953760	10.1631/jzus.B2200016	2022	HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.	MYC
35960849	10.1182/blood.2022016428	2022	Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma.	MYC
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	MYC
36001789	10.46883/2022.25920970	2022	Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.	MYC
36006771	10.1097/PAS.0000000000001957	2022	Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study.	MYC
36040107	10.1002/JLB.6MA0822-720RR	2022	Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study.	MYC
36051037	10.1002/jha2.475	2022	B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens.	MYC
36051055	10.1002/jha2.457	2022	An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.	MYC
36057749	10.1007/s00428-022-03404-6	2022	Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.	MYC
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	MYC
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	MYC
33120427	10.1182/blood.2020007193	2021	The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.	MYC
33303632	10.1074/jbc.RA120.015285	2021	A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation.	MYC
33306213	10.1002/ajh.26068	2021	First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.	MYC
33340851	10.1016/j.leukres.2020.106491	2021	Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia.	MYC
33360122	10.1016/j.cancergen.2020.12.004	2021	RNA-Based next generation sequencing complements but does not replace fluorescence in situ hybridization studies for the classification of aggressive B-Cell lymphomas.	MYC
33392349	10.22038/AOJNMB.2020.48887.1332	2021	Incremental Value of FDG PET/CT in Aggressive High Grade B Cell lymphoma with TdT Expression.	MYC
33393079	10.1111/his.14327	2021	Radiologically guided percutaneous core needle biopsy of the spleen: a reliable and safe diagnostic procedure for neoplastic and reactive conditions.	MYC
33399078	10.1016/j.esmoop.2020.100012	2021	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.	MYC
33480087	10.1002/hon.2839	2021	High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.	MYC
33480830	10.1080/10428194.2020.1869965	2021	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.	MYC
33521119	10.12998/wjcc.v9.i2.482	2021	Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report.	MYC
33530253	10.1097/MD.0000000000024449	2021	Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.	MYC
33548250	10.1016/j.humpath.2021.01.006	2021	Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.	MYC
33551436	10.3960/jslrt.20043	2021	DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.	MYC
33591648	10.1002/brb3.2061	2021	New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).	MYC
33610538	10.1016/j.oooo.2020.11.005	2021	Oral and oropharyngeal diffuse large B-cell lymphoma and high-grade B-cell lymphoma: A clinicopathologic and prognostic study of 69 cases.	MYC
33654205	10.1038/s41375-021-01181-w	2021	BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.	MYC
33655392	10.1007/s00428-021-03050-4	2021	The Burkitt-like immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.	MYC
33672644	10.3390/cancers13040887	2021	Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements.	MYC
33683983	10.1177/1093526621999022	2021	EBV-Positive Plasmacytomas Involving a Nasopharyngeal Angiofibroma in an Adolescent.	MYC
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	MYC
33768318	10.1007/s00428-021-03084-8	2021	High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.	MYC
33771538	10.1016/j.humpath.2021.03.006	2021	MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.	MYC
33775465	10.1016/j.blre.2021.100824	2021	Revisiting Richter transformation in the era of novel CLL agents.	MYC
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	MYC
33799592	10.3390/ijms22062841	2021	Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.	MYC
33807449	10.3390/cancers13071620	2021	High-Grade B-Cell Lymphoma (HGBL) with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan.	MYC
33809641	10.3390/cancers13061340	2021	Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms.	MYC
33816589	10.3389/fvets.2021.647009	2021	Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma.	MYC
33858042	10.3760/cma.j.issn.0253-2727.2021.02.006	2021	[The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].	MYC
33899787	10.1097/PAS.0000000000001691	2021	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.	MYC
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	MYC
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	MYC
34007370	10.14740/jh818	2021	<i>MYC</i>-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A Diagnostic and Therapeutic Challenge.	MYC
34017010	10.1038/s41597-021-00915-w	2021	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set.	MYC
34051685	10.1016/j.ejrad.2021.109784	2021	Differentiation between primary CNS lymphoma and atypical glioblastoma according to major genomic alterations using diffusion and susceptibility-weighted MR imaging.	MYC
34078046	10.3760/cma.j.cn112151-20201223-00953	2021	[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].	MYC
34078047	10.3760/cma.j.cn112151-20210204-00127	2021	[Clinicopathological and molecular genetic features of Burkitt-like lymphoma with 11q aberration].	MYC
34091974	10.1111/jop.13209	2021	Burkitt lymphoma of the head and neck: An international collaborative study.	MYC
34097157	10.1007/s11864-021-00857-w	2021	Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.	MYC
34099699	10.1038/s41467-021-23695-8	2021	Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing.	MYC
34101913	10.1111/jop.13208	2021	Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis.	MYC
34105464	10.19746/j.cnki.issn.1009-2137.2021.03.012	2021	[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].	MYC
34105893	10.1002/cam4.4062	2021	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.	MYC
34113336	10.3389/fimmu.2021.599493	2021	<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.	MYC
34123811	10.3389/fonc.2021.656219	2021	Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma.	MYC
34171161	10.1111/pin.13131	2021	Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphoma.	MYC
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	MYC
34221962	10.3389/fonc.2021.638154	2021	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.	MYC
34255748	10.1172/JCI143119	2021	Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia.	MYC
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	MYC
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	MYC
34282799	10.3390/cancers13133369	2021	The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.	MYC
34307232	10.4322/acr.2021.278	2021	De novo double-hit B-cell precursor leukemia/lymphoma - an unusual presentation as peritoneal lymphomatosis.	MYC
34318932	10.1111/bjh.17734	2021	MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.	MYC
34334687	10.1097/PAS.0000000000001726	2021	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.	MYC
34363012	10.1038/s41375-021-01376-1	2021	CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.	MYC
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	MYC
34380369	10.1080/10428194.2021.1964021	2021	Whole genome sequencing demonstrates substantial pathophysiological differences of <i>MYC</i> rearrangements in patients with plasma cell myeloma and B-cell lymphoma.	MYC
34384155	10.3760/cma.j.issn.0253-2727.2021.06.008	2021	[Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].	MYC
34388250	10.1093/jnen/nlab080	2021	Expression of STAT6 and Phosphorylated STAT6 in Primary Central Nervous System Lymphomas.	MYC
34399819	10.1186/s40170-021-00263-8	2021	Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.	MYC
34404436	10.1186/s13027-021-00396-x	2021	Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China.	MYC
34412631	10.1186/s12935-021-02143-z	2021	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling.	MYC
34424958	10.1182/blood.2021012052	2021	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.	MYC
34437837	10.1016/j.molcel.2021.07.041	2021	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.	MYC
34438040	10.1016/j.annonc.2021.08.1991	2021	SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.	MYC
34455369	10.1016/j.bbrc.2021.08.051	2021	Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.	MYC
34465776	10.1038/s41467-021-25405-w	2021	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.	MYC
34477080	NA	2021	Indurated Plaques on the Legs: Think Lymphoma.	MYC
34500469	10.1182/bloodadvances.2021004635	2021	Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.	MYC
34534532	10.1016/j.ejphar.2021.174505	2021	7-[[(4-methyl-2-pyridinyl)amino](2-pyridinyl)methyl]-8-quinolinol (compound 30666) inhibits enhancer activity and reduces B-cell lymphoma growth - A question of specificity.	MYC
34551904	10.1158/1078-0432.CCR-21-1067	2021	Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.	MYC
34557659	10.1016/j.isci.2021.102931	2021	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.	MYC
34581757	10.1182/bloodadvances.2021004619	2021	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.	MYC
34584457	10.2147/CMAR.S317319	2021	Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.	MYC
34588837	10.2147/BLCTT.S330008	2021	Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission.	MYC
34624215	10.1016/j.molcel.2021.09.009	2021	Sex, life, and death in MYC-driven lymphomagenesis.	MYC
34625792	10.1182/bloodadvances.2021005682	2021	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.	MYC
34627430	10.19746/j.cnki.issn.1009-2137.2021.05.019	2021	[Clinical Characteristics and Prognosis Affecting-Factors of the Patients with Burkitt Lymphoma].	MYC
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	MYC
34671837	10.1007/s00292-021-01011-x	2021	[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].	MYC
34679437	10.3390/diagnostics11101739	2021	Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis.	MYC
34680290	10.3390/cancers13205141	2021	Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents.	MYC
34698437	10.1111/jcmm.16999	2021	Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.	MYC
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	MYC
34707037	10.3960/jslrt.21025	2021	t(9;14)(p13;q32)/PAX5-IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma.	MYC
34732441	10.21873/anticanres.15384	2021	Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.	MYC
34742294	10.1186/s13000-021-01163-7	2021	Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.	MYC
34763718	10.1186/s13046-021-02159-3	2021	ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.	MYC
34782660	10.1038/s41598-021-01693-6	2021	Primary central nervous system lymphomas express immunohistochemical factors of autophagy.	MYC
34806851	10.20892/j.issn.2095-3941.2021.0193	2021	Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.	MYC
34830747	10.3390/cancers13225592	2021	Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era.	MYC
34858727	10.1080/2162402X.2021.2003533	2021	Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.	MYC
34889402	10.1182/hematology.2021000247	2021	Double-hit lymphoma: optimizing therapy.	MYC
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	MYC
34945004	10.3390/cancers13246384	2021	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.	MYC
34956871	10.3389/fonc.2021.746577	2021	Clinical Features and Prognostic Significance of <i>NOTCH1</i> Mutations in Diffuse Large B-Cell Lymphoma.	MYC
35004320	10.3389/fonc.2021.795330	2021	Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With <i>MYC</i> and <i>BCL6</i> Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?	MYC
35116484	10.21037/tcr-20-2748	2021	Double hit B-lymphoblastic lymphoma with concurrent <i>IGH</i>/<i>BCL2</i> and 8q24/<i>MYC</i> translocations: a case report.	MYC
31399522	10.3324/haematol.2019.223891	2020	An increase in <i>MYC</i> copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.	MYC
31844144	10.1038/s41375-019-0691-6	2020	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.	MYC
31991488	10.1111/apm.13029	2020	EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.	MYC
32074595	10.1159/000505892	2020	The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.	MYC
32101329	10.1002/hon.2727	2020	Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.	MYC
32334477	10.31557/APJCP.2020.21.4.1103	2020	The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.	MYC
32350066	10.1158/0008-5472.CAN-19-2247	2020	FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.	MYC
32497402	10.1002/cyto.b.21887	2020	Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.	MYC
32566654	10.1155/2020/1350820	2020	Prognostic Value of Concurrent Expression of C-MYC and BCL2 in Intravascular Large B-Cell Lymphoma: A 10-Year Retrospective Study.	MYC
32722781	10.1182/bloodadvances.2020001551	2020	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.	MYC
32889391	10.1016/j.anndiagpath.2020.151610	2020	Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.	MYC
32921221	10.1080/10428194.2020.1815017	2020	Clinicopathological and prognostic significance of <i>BCL2</i>, <i>BCL6</i>, <i>MYC</i>, and <i>IRF4</i> copy number gains and translocations in follicular lymphoma: a study by FISH analysis.	MYC
32991338	10.1097/PAS.0000000000001577	2020	High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.	MYC
33168821	10.1038/s41408-020-00382-3	2020	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.	MYC
33298918	10.1038/s41467-020-20136-w	2020	Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.	MYC
33365186	10.25259/SNI_314_2020	2020	Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.	MYC
30306208	10.1007/s00277-018-3498-z	2019	MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.	MYC
30737994	10.1111/ejh.13219	2019	Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-Identifies a subgroup of patients with poor outcome.	MYC
31127909	10.31557/APJCP.2019.20.5.1463	2019	C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma	MYC
31315646	10.1186/s13000-019-0856-7	2019	Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.	MYC
31498031	10.1200/JCO.19.00743	2019	Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.	MYC
29666157	10.1136/jclinpath-2018-205039	2018	CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.	MYC
29708579	10.5146/tjpath.2018.01430	2018	Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma.	MYC
29801406	10.22034/APJCP.2018.19.5.1229	2018	Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience	MYC
30015962	10.3892/or.2018.6581	2018	Knockdown of metadherin inhibits cell proliferation and migration in colorectal cancer.	MYC
30043475	10.1002/dc.24038	2018	Triple hit lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.	MYC
30113335	10.1097/PAS.0000000000001132	2018	High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.	MYC
30115641	10.1182/bloodadvances.2018016048	2018	Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.	MYC
28212447	10.1371/journal.pone.0172364	2017	Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.	MYC
28327893	10.1093/annonc/mdx022	2017	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.	MYC
28351934	10.1182/blood-2016-11-747022	2017	Genetic profiling of <i>MYC</i> and <i>BCL2</i> in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.	MYC
28368423	10.1038/onc.2017.95	2017	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.	MYC
28914785	10.3390/ijms18091986	2017	Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.	MYC
28952038	10.1007/s11912-017-0629-y	2017	Double-Hit Large B Cell Lymphoma.	MYC
29044419	10.1093/jnen/nlx083	2017	MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.	MYC
29088292	10.1371/journal.pone.0186983	2017	Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.	MYC
29198442	10.1016/j.trecan.2017.09.008	2017	Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma.	MYC
26119939	10.1038/onc.2015.245	2016	Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.	MYC
26390147	10.3109/10428194.2015.1096352	2016	Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.	MYC
26421520	10.3109/10428194.2015.1101099	2016	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.	MYC
26448193	10.1097/PAS.0000000000000542	2016	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.	MYC
26565895	10.1002/cncr.29781	2016	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.	MYC
26573234	10.18632/oncotarget.6262	2016	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.	MYC
27071312	10.3109/10428194.2016.1167205	2016	Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.	MYC
27282353	10.1038/modpathol.2016.114	2016	Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.	MYC
27286976	10.1186/s12885-016-2397-8	2016	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.	MYC
27391453	10.1097/DAD.0000000000000607	2016	Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.	MYC
27490482	10.7554/eLife.18270	2016	MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs.	MYC
27544800	10.1016/j.humpath.2016.07.025	2016	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.	MYC
24679006	10.3109/10428194.2014.907896	2015	TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.	MYC
25103070	10.1038/modpathol.2014.95	2015	B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.	MYC
25284491	10.3109/10428194.2014.970550	2015	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.	MYC
25359993	10.1182/blood-2014-08-594507	2015	Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.	MYC
25741152	10.3748/wjg.v21.i8.2433	2015	Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.	MYC
25828389	10.1097/PAS.0000000000000433	2015	MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.	MYC
25828391	10.1097/PAS.0000000000000434	2015	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.	MYC
26158410	10.18632/oncotarget.4073	2015	MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.	MYC
26515759	10.1186/s13045-015-0218-1	2015	Establishment and characterization of a novel MYC/BCL2 double-hit diffuse large B cell lymphoma cell line, RC.	MYC
26558423	10.3109/08880018.2015.1087611	2015	De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis.	MYC
26634708	10.1007/s11864-015-0374-0	2015	Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.	MYC
26717387	10.1097/MD.0000000000002388	2015	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.	MYC
24118498	10.1111/ejh.12212	2014	MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations.	MYC
24398325	10.1182/blood-2013-06-507996	2014	A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.	MYC
24503701	10.1371/journal.pone.0087456	2014	Immunohistochemistry for myc predicts survival in colorectal cancer.	MYC
24614102	10.1172/JCI63139	2014	CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis.	MYC
25090026	10.1371/journal.pone.0104068	2014	MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.	MYC
25125624	10.1309/AJCPBWVHTF7RRSA4	2014	Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.	MYC
25261932	10.1038/ng.3105	2014	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.	MYC
25297597	10.3760/cma.j.issn.1003-9406.2014.01.020	2014	[Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].	MYC
22484426	10.1038/onc.2012.117	2013	Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.	MYC
23335369	10.1182/blood-2012-06-435842	2013	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.	MYC
23449635	10.1182/blood-2012-10-460063	2013	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.	MYC
23538750	10.1038/leu.2013.94	2013	Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.	MYC
23770605	10.1038/ng.2652	2013	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.	MYC
23939148	10.1097/PAP.0b013e3182a289f2	2013	MYC/BCL2 double-hit high-grade B-cell lymphoma.	MYC
23982173	10.1182/blood-2013-02-484055	2013	Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.	MYC
24009228	10.1182/blood-2013-05-498329	2013	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.	MYC
24169826	10.1182/blood-2012-12-473090	2013	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.	MYC
20981461	10.1007/s10006-010-0254-5	2012	Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin 'double-hit' lymphoma: report of a case.	MYC
22002575	10.1038/modpathol.2011.147	2012	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.	MYC
22393362	10.1371/journal.pone.0031366	2012	Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.	MYC
22661084	10.4049/jimmunol.1102277	2012	B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels.	MYC
22804688	10.1111/j.1365-2559.2012.04301.x	2012	High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis.	MYC
22851565	10.1200/JCO.2011.41.0985	2012	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	MYC
23042398	10.3760/cma.j.issn.1003-9406.2012.05.017	2012	[Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].	MYC
23079660	10.1016/j.ccr.2012.09.003	2012	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.	MYC
21628855	10.3960/jslrt.51.7	2011	BCL2 and MYC dual-hit lymphoma/leukemia.	MYC
21640157	10.1016/j.exphem.2011.05.002	2011	Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.	MYC
21783402	10.1016/j.oraloncology.2011.06.506	2011	Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas.	MYC
20087644	10.1007/s10552-010-9504-y	2010	Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma.	MYC
20118770	10.1097/PAS.0b013e3181cd3aeb	2010	B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.	MYC
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	MYC
19535347	10.3324/haematol.2008.005355	2009	Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.	MYC
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	MYC
19597184	10.1182/blood-2009-03-212191	2009	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.	MYC
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	MYC
18235046	10.1182/blood-2007-08-108654	2008	PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.	MYC
18426731	10.1309/CMPGPYTMFRM6RVQR	2008	Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene.	MYC
18713946	10.1182/blood-2008-03-147645	2008	MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.	MYC
18752503	10.1111/j.1365-2559.2008.03076.x	2008	MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.	MYC
16690525	10.1080/10428190500361128	2006	Expression of ice, bcl-2, c-myc and p53 in different bone marrow cell populations from patients with diffuse large B-cell lymphoma.	MYC
15716988	10.1038/sj.leu.2403661	2005	Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas.	MYC
15191563	10.1111/j.0022-202X.2004.22720.x	2004	Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas.	MYC
12562237	10.5858/2003-127-208-EOPMOB	2003	Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.	MYC
12036888	10.1182/blood.v99.12.4554	2002	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.	MYC
